Press Releases

June 27, 2024 Lupin Receives Tentative Approval from U.S. FDA for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)

June 22, 2024 Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility

June 17, 2024 Lupin Appoints Abdelaziz Toumi as CEO of its API CDMO Subsidiary

June 14, 2024 Lupin Announces Closure of US FDA Inspection at its Injectable Facility with Zero 483 Observations

June 12, 2024 Lupin and Fuji Sign License and Supply Agreement for Commercialization of Nextstellis™ in Vietnam and Philippines

June 5, 2024 Lupin Completes Acquisition of two Brands from Sanofi in Europe and Canada

June 3, 2024 Lupin Receives Tentative Approval from U.S. FDA for Letermovir Tablets

June 3, 2024 Lupin Launches Doxycycline for Injection USP in the United States

May 16, 2024 Lupin Receives Approval from U.S. FDA for Midostaurin Capsules